Pfizer wins unconditional EU antitrust okay for $43 bln Seagen buy

The European Commission granted pharmaceutical giant Pfizer unconditional EU antitrust approval for its acquisition of Bothell-based biotech company Seagen.

The acquisition, announced in March of 2023, is Pfizer’s largest recent purchase. The addition of Seagen’s cancer therapies will broaden and strengthen Pfizer’s existing portfolio.

The European Commission stated that the merger will not create significant concerns around industry competition or drug pricing.

READ THE STORY at Reuters »